Main > ONCOLOGY (**) > Leukemia>Myeloid>Acute>IDH1+ R/R > Treatment > FR. S. Ivosidenib 250 mg Tab.

---

FR. S. Ivosidenib 250 mg Tab.'s subsections
(*) USA Approval Date: 2018. 07.20.
Companion Diagnostics>
Company
Patent>Assignee; Claims; No.; Etc.
Patent>UpDate: 2018. 07.17.
TradeMark
TradeMark Web-Site

FR. S. Ivosidenib 250 mg Tab.'s products
This section has no products